2023
Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).
Couvillon A, Turkbey B, Choyke P, Lee-Wisdom K, McKinney Y, Sidlow R, Mullane M, Giri V, Morgan T, Cheng H, Merino M, Figg W, Pinto P, Dahut W, Karzai F. Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI). Journal Of Clinical Oncology 2023, 41: 390-390. DOI: 10.1200/jco.2023.41.6_suppl.390.Peer-Reviewed Original ResearchGermline pathogenic variantsProstate cancerActive surveillancePathogenic variantsMedian ageRadiation therapyMonitoring of PCaDiagnosis of PCaDistinct pathogenic variantsHigh-risk geneticsPIRADS 3 lesionsPIRADS 4 lesionsISUP grade group 1Grade group 1Localized prostate cancerMonoallelic pathogenic variantsDNA mismatch repair genesLikely pathogenic variantsProstate cancer diagnosisMismatch repair genesDefinitive treatmentPSA monitoringProstate biopsyBiopsy specimensRisk factors
2017
Insurance status and patterns of late diagnosis and cancer treatment: A population-based study.
Lu-Yao G, He J, Giri V, Klassen A. Insurance status and patterns of late diagnosis and cancer treatment: A population-based study. Journal Of Clinical Oncology 2017, 35: e16553-e16553. DOI: 10.1200/jco.2017.35.15_suppl.e16553.Peer-Reviewed Original ResearchNon-Medicaid insurancePopulation-based studyLate diagnosisUninsured patientsLocalized cancerInsurance statusRadical prostatectomyDiagnosis periodEnd Results (SEER) databaseLocalized prostate cancerMarital statusProstate cancer patientsProstate cancer diagnosisLogistic regression modelsResults databaseRegional diseaseCancer patientsInsurance typeRelative riskMedicaid patientsProstate cancerPatientsAge 65Veterans AffairsPrivate insurance
2009
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population
Kaplan D, Boorjian S, Ruth K, Egleston B, Chen D, Viterbo R, Uzzo R, Buyyounouski M, Raysor S, Giri V. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population. BJU International 2009, 105: 334-337. PMID: 19709072, PMCID: PMC2809782, DOI: 10.1111/j.1464-410x.2009.08793.x.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramProstate Cancer Prevention Trial Risk CalculatorProstate cancer riskHigh-risk menProstate cancerPSA levelsRisk scoreFamily historyAfrican American menPCPT calculatorRisk calculatorCancer riskLower baseline prostate-specific antigen levelsBaseline prostate-specific antigen levelLow baseline PSA levelsProstate-specific antigen levelCancer Risk Assessment ProgramBaseline PSA levelsMedian PSA levelRisk of diagnosisBaseline risk scoreMedian risk scoreProstate cancer ratesProstate cancer diagnosisPrevious biopsy